L
Lawrence Tamarkin
Researcher at National Institutes of Health
Publications - 99
Citations - 7416
Lawrence Tamarkin is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Melatonin & Circadian rhythm. The author has an hindex of 41, co-authored 99 publications receiving 7045 citations. Previous affiliations of Lawrence Tamarkin include St. Elizabeths Hospital.
Papers
More filters
Journal ArticleDOI
Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery
Giulio F. Paciotti,Lonnie D. Myer,David M. Weinreich,Dan V. Goia,Nicolae Pavel,Richard E. McLaughlin,Lawrence Tamarkin +6 more
TL;DR: PT-cAu-TNF was less toxic and more effective in reducing tumor burden than native TNF since maximal antitumor responses were achieved at lower doses of drug.
Journal ArticleDOI
Melatonin: A Coordinating Signal for Mammalian Reproduction?
TL;DR: In seasonally breeding mammals that use changes in the photoperiod to time their reproductive cycles, temporal signals to the reproductive system are controlled by the daily rhythm in melatonin production.
Journal ArticleDOI
Phase I and pharmacokinetic studies of CYT-6091, a novel PEGylated colloidal gold-rhTNF nanomedicine.
Steven K. Libutti,Giulio F. Paciotti,Adriana A. Byrnes,H. Richard Alexander,H. Richard Alexander,William E. Gannon,Melissa Walker,Geoffrey D. Seidel,Nargiza Yuldasheva,Nargiza Yuldasheva,Lawrence Tamarkin +10 more
TL;DR: These data indicate that rhT NF formulated as CYT-6091 may be administered systemically at doses of rhTNF that were previously shown to be toxic and that CYTs may target to tumors.
Journal ArticleDOI
Colloidal gold nanoparticles: a novel nanoparticle platform for developing multifunctional tumor‐targeted drug delivery vectors
TL;DR: This work discusses the development of colloidal gold‐based drugs that are designed to target the delivery of TNF and paclitaxel to solid tumors and attempts to build such multifunctional nanotherapeutics using colloidalgold nanoparticles.
Journal ArticleDOI
Nanomedicines: addressing the scientific and regulatory gap
Sally S. Tinkle,Scott E. McNeil,Stefan Mühlebach,Raj Bawa,Gerrit Borchard,Yechezkel Barenholz,Lawrence Tamarkin,Neil P. Desai +7 more
TL;DR: It is critical to work to close the scientific and regulatory gaps to assure that nanomedicine drives the next generation of biomedical innovation.